The full context
The record of Dr. Goodenowe's work in Saskatchewan is not fully understood without knowing what happened to the company he built, the technology he developed, and the compounds he designed.
Phenomenome Discoveries
On December 19, 2000, Dr. Goodenowe incorporated a Saskatoon-based numbered company as a wholly-owned subsidiary of his holding company, Yolbolsum Canada Inc. (YBCI). On March 15, 2001, the company was renamed Phenomenome Discoveries Inc. (PDI). Over the next 15 years, PDI grew to approximately 50 employees, developed a patented metabolomics platform, published dozens of peer-reviewed studies, and conducted the largest colon cancer screening trial in Saskatchewan history.
Dr. Goodenowe was never a PDI employee. His services as President and CEO were provided through YBCI under a management services agreement. In January 2008, an independent review by Deloitte and Touche found that his compensation was below the 25th percentile of comparable Canadian companies. YBCI has never received employer benefits or stock options from PDI.
In late 2015, Golden Opportunities Fund Inc. (GOFI), a Saskatchewan-based labour-sponsored venture capital fund managed by Westcap Mgt. Ltd. and one of PDI's principal institutional investors, demanded immediate repayment of an $833,000 loan secured against laboratory equipment. PDI was unable to repay. On February 19, 2016, the PDI board voted in favour of receivership. On February 26, 2016, the company entered court-ordered receivership. The court-supervised receivership process is documented publicly.
What PDI was worth
In June 2015, PriceWaterhouseCoopers valued PDI's diagnostics and therapeutics programs at $100,000,000. A private valuation of PDI's rare disease program at the same time placed it at over $327,000,000.
In its annual report dated August 31, 2015, GOFI valued PDI at $70.00 per share, representing a total enterprise value of $133,514,150. This valuation was published in a publicly filed financial document reviewed by GOFI's auditors and approved by GOFI's Board of Directors.
On September 16, 2016, all of PDI's assets were sold through the court-supervised receivership process for just under $5,000,000.
$133.5M
GOFI's own valuation of PDI (August 31, 2015 annual report)
<$5M
Price paid for all PDI assets (September 16, 2016)
$833K
The equipment loan debt that triggered receivership
Who financed PDI
The financing record before the receivership
The CBC reporting has presented some PDI investors as people who lost money on a Saskatchewan biotech. The financing record contained in Dr. Goodenowe's October 2016 written account documents who actually put money into the company in its final two years.
From September 2014 onward, Dr. Goodenowe, through his holding company Yolbolsum Canada Inc. (YBCI), was the only PDI shareholder providing the company with debt or equity financing. By August 31, 2016, PDI owed YBCI $3,697,659.80 under an unsecured loan agreement signed September 15, 2014, plus $200,000 in unpaid licensing fees and $38,396 in unpaid expenses going back to November 2014.
Dr. Goodenowe's account records that he funded those advances by liquidating personal and family assets. He sold the certified seed and commodity inventory of Goodnough Farms Ltd., his family farm, at a significant discount to its proper-season value. He exhausted his personal cash reserves. He sold most of the farm equipment at auction for $124,907.40, equipment he records was worth more than $300,000 if sold privately. He listed the farmland for sale. On March 15, 2016, he sold Goodnough Farms Ltd. itself for $2,150,000.
When the personal asset sales could not generate liquidity fast enough, Dr. Goodenowe approached Golden Opportunities Fund Inc. (GOFI) in November 2014 for a $700,000 bridge loan against the family farmland, which he records carried more than $1,500,000 in equity. The intent of the loan, according to Dr. Goodenowe's account, was to flow directly into PDI: GOFI would advance funds to YBCI, YBCI would in turn advance them to PDI, and when PDI repaid YBCI, YBCI would repay GOFI. GOFI ultimately deposited the loan funds directly into PDI's bank account. GOFI's chief operating officer, Doug Banzet, declined the bridge-loan terms Dr. Goodenowe initially proposed. According to Dr. Goodenowe's account, GOFI required the following conditions instead: a demand loan structure with ten-day notice for repayment; $1,000,000 in principal rather than $700,000; 36% annual interest, compounded monthly; mortgage on all GFL property; security against YBCI's foundational patent and license to PDI; security against all present and after-acquired YBCI property; and a covenant that YBCI could not loan additional funds to PDI without GOFI's written consent.
Dr. Goodenowe's account records that he initially refused those terms in writing on December 12, 2014, and that Banzet then telephoned him to provide a verbal personal assurance that GOFI would not call the loan unless YBCI itself called its loan on PDI, and that GOFI's intentions were aligned with preventing PDI bankruptcy. Dr. Goodenowe signed the documents that day. He records that he would not have signed them without that assurance.
The account further records that GOFI subsequently used the consent clause to systematically block YBCI from advancing further capital to PDI as the company ran out of operating cash. Section V of Dr. Goodenowe's October 2016 written account is titled "GOFI's behavior of fraudulent misrepresentation, bad faith, and extortion relating to the YBCI-GOFI loan agreement of December 12, 2014." None of these characterizations have been adjudicated.
On March 18, 2016, three weeks after the receivership order, YBCI repaid the GOFI loan in full: $1,570,383.65, comprising $1,000,000 in principal, $553,663.67 in interest (which Dr. Goodenowe's account calculates as a 40% effective annual rate), and $16,719.98 in legal fees. The account specifies that the repayment was funded entirely from non-PDI assets under Dr. Goodenowe's control, primarily the proceeds of the Goodnough Farms sale. YBCI received nothing from PDI toward its loan.
The two recoveries read together. The $1,000,000 in operating capital that GOFI deposited into PDI's bank account in December 2014 was repaid by Dr. Goodenowe personally, from the proceeds of the Goodnough Farms sale, with $553,663.67 in interest and $16,719.98 in legal fees on top. PDI's assets, including the patents and platforms valued in GOFI's own audited filings at $133,514,150, were acquired through the receivership for under $5,000,000. None of GOFI's $1,570,383.65 recovery came from the receivership distribution. It came from Dr. Goodenowe.
The receivership distribution wiped out YBCI's claim entirely. As of November 30, 2015, the major outstanding debt obligations of PDI recorded in Dr. Goodenowe's account were: GOFI, partially secured, approximately $1,100,000; YBCI, unsecured, approximately $2,900,000; patent lawyers, unsecured, approximately $500,000; and the landlord, unsecured, approximately $1,500,000. The PDI assets were sold through the receivership for under $5,000,000. GOFI was paid in full. Every unsecured creditor received nothing. YBCI was the largest of those unsecured creditors.
The financing record is verifiable from the unsecured loan agreement signed September 15, 2014, the GOFI–YBCI loan documentation of December 12, 2014, the receivership filings, and the contemporaneous email correspondence between Dr. Goodenowe and Doug Banzet preserved as exhibits to Dr. Goodenowe's October 2016 written account.
The principals
GOFI was the institutional investor that initiated the receivership. Its CEO is Grant Kook. Its COO, Doug Banzet, was a PDI board director and chairman of PDI's audit and finance committee throughout the events described here. Westcap Mgt. Ltd. is GOFI's fund manager.
The assets were acquired by Med-Life Discoveries LP (MLD), a limited partnership formed in June 2015, prior to the receivership. MLD's principals included GOFI (holding a 50% share), L. David Dube of Concorde Centres Inc., and Greg Yuel of PIC Investments Inc. MLD was not a PDI shareholder.
Med-Life Discoveries is now led by Dr. Shawn Ritchie (CEO) and Dr. Tara Smith (EVP of Clinical Development). Both were formerly researchers at Phenomenome Discoveries under Dr. Goodenowe. Med-Life operates from Suite 407, 15 Innovation Blvd, Saskatoon, the same Innovation Place campus where Phenomenome Discoveries was headquartered.
A conflict of interest not reported by CBC
CBC Saskatchewan's tenth article in its series on Dr. Goodenowe, published March 30, 2026, featured Peter Blaney as its primary investor witness. CBC did not disclose that Blaney co-founded GraySpace Therapeutics following the PDI receivership, with the company formed to commercialize the resulting intellectual property including PPI-1011.
Peter Blaney was the authorized representative of Dynex Capital Limited Partnership, Tancho Capital 1 Limited Partnership, Tancho Capital 3 Limited Partnership, and Induran Ventures 1 Limited Partnership, a group of PDI shareholders with the combined power to veto finance-related PDI board resolutions. According to Dr. Goodenowe's October 2016 written account, Blaney voted in favour of the PDI receivership on February 19, 2016. Barry Markowsky, who according to the same account also voted in favour of the receivership, became GraySpace's CEO.
GraySpace Therapeutics has been dormant since late 2021. PPI-1011 has since been fully reconsolidated under Med-Life Discoveries LP. No current financial link between Blaney and MLD or PPI-1011 has been confirmed.
The conflict of interest is grounded in the sequence of events: Blaney voted for the receivership that transferred control of the IP, then co-founded a company to commercialize it. These relationships were not disclosed in CBC's reporting. Readers can review the primary source documents and draw their own conclusions.
What was sold
Through the receivership, the following assets were acquired by Med-Life Discoveries LP for just under $5,000,000:
The patent portfolio
Twenty patent families, of which Dr. Goodenowe was the sole or co-inventor of 16.
PPI-1011 and the plasmalogen precursor compounds
Co-invented by Dr. Goodenowe. Now the basis of the only Health Canada-approved human trial for RCDP, conducted by Med-Life Discoveries. See the RCDP research →
The cancer assessment technology
GTA-446 / COLOGIC detected 86% of colorectal cancers in the Saskatchewan trial. Not continued as a commercial product by the successor entity.
Laboratory equipment and research staff
Including Dr. Shawn Ritchie and Dr. Tara Smith, who now lead Med-Life Discoveries.
What happened to the cancer assessment technology
The GTA-446 blood assessment, which detected 86% of colorectal cancers in the Saskatchewan trial, was not continued as a commercial product by the successor entity. The technology was effectively set aside.
In July 2024, the FDA approved Shield, the first blood test for primary colorectal cancer assessment. Its published sensitivity: 83.1%. The PDI trial in Saskatchewan had reported 86% detection fourteen years earlier. The two technologies use different mechanisms, and direct comparison requires caution. What is documented is that the concept was demonstrated in Saskatoon more than a decade before the FDA approved a blood-based test elsewhere, and that the Saskatchewan-developed technology did not survive the receivership.
What happened next
Dr. Goodenowe resigned as PDI's President and CEO on July 5, 2016, before the September 16, 2016 court-approved sale of PDI's assets. The next day, on July 6, 2016, Prodrome Sciences Inc. (PSI) was incorporated. Prodrome Health Centers Inc. (PHCI) was incorporated subsequently. Both companies operate within YBCI's broader corporate structure.
In the years that followed, Dr. Goodenowe's work continued under these new corporate vehicles. PSI developed and brought to market the Prodrome blood assessment platform now used by more than 3,000 health professionals worldwide. PHCI eventually became the operational basis for the Lakeview Regional Wellness Centre and the broader Moose Jaw Vitality Project.
Med-Life Discoveries v. Yolbolsum Canada Inc. et al. (2019)
On June 7, 2019, Med-Life Discoveries LP filed a Statement of Claim in the Court of Queen's Bench for Saskatchewan, Judicial Centre of Saskatoon, against Yolbolsum Canada Inc. (YBCI), Prodrome Sciences Inc., Prodrome Health Centers Inc., Dr. Goodenowe personally, and a long list of additional defendants including Prodrome and PHCI senior employees. The court file number is QB 839 of 2019. The action is ongoing.
The substance of the dispute concerns alleged use of intellectual property and technology. Dr. Goodenowe's position, set out in his draft Statement of Defence, is that the underlying technology, a method of non-targeted complex sample analysis (NTCSA), was invented by him and held by YBCI before being licensed to PDI on December 15, 2001. On this account, the IP is therefore owned by YBCI, not by PDI or its successor. The defence further notes that patents, by their nature, require public disclosure, so PDI's patented IP is not protected as a trade secret.
None of the allegations in the 2019 Statement of Claim have been proven in court.
Questions that have not been asked
GOFI valued PDI at $133.5 million in its August 31, 2015 annual report. Within months, GOFI demanded immediate repayment of an $833,000 equipment loan, and proceedings led to a court-ordered receivership on February 26, 2016. These facts are documented in GOFI's own audited public filing and the receivership record. They have not been examined in CBC's reporting.
The GOFI debenture was secured against laboratory equipment only. PDI's intellectual property was explicitly excluded from that security. The receivership nonetheless resulted in the sale of the entire IP portfolio. These facts are documented in the receivership record. They have not been examined in CBC's reporting.
Med-Life Discoveries LP was formed in June 2015, before the receivership. GOFI held a 50% share. MLD was the sole bidder when PDI's assets came to sale. These facts are documented in the public receivership record. They have not been examined in CBC's reporting.
YBCI, as PDI's majority shareholder and its largest unsecured creditor, was owed more than $3.9 million and received nothing. No other PDI shareholders received anything. MLD acquired all assets for just under $5 million. These facts are documented in the receivership record and in Dr. Goodenowe's October 2016 written account. They have not been examined in CBC's reporting.
GOFI's $1,570,383.65 recovery on its December 2014 loan to YBCI was paid in full by Dr. Goodenowe personally, from the proceeds of the Goodnough Farms sale, and not from the receivership distribution. This is documented in Dr. Goodenowe's October 2016 written account. It has not been examined in CBC's reporting.
Peter Blaney, CBC's primary investor witness, co-founded GraySpace Therapeutics following the PDI receivership, with the company formed to commercialize PPI-1011. Blaney voted for the receivership. These facts are documented in Dr. Goodenowe's October 2016 written account and MLD's own press release. They were not disclosed in CBC's reporting.
The cancer assessment technology that detected 86% of colorectal cancers in Saskatchewan was set aside after the receivership. No explanation has been published. The technology has never been continued as a commercial product. This fact is documented in the public receivership record and the published research. It has not been examined in CBC's reporting.
These are questions, not accusations. The primary source documents are publicly available. The receivership record is online. Dr. Goodenowe's October 2016 written account is in the record. The GOFI semi-annual report is an audited public filing. The answers may be straightforward. What is documented is that they have not been asked.
See everything in chronological order
The complete timeline →